Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy

Sarah E Lochrin; Hannah L Kalvin; James W Smithy; Monica F Chen; Parisa Momtaz; Alexander N Shoushtari; Katherine S Panageas; Michael A Postow

doi:10.1001/jamaoncol.2024.6168

Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy

JAMA Oncol. 2025 Mar 1;11(3):349-351. doi: 10.1001/jamaoncol.2024.6168.

Authors

Sarah E Lochrin¹, Hannah L Kalvin², James W Smithy^{1

3}, Monica F Chen^{1

3}, Parisa Momtaz^{1

3}, Alexander N Shoushtari^{1

3}, Katherine S Panageas², Michael A Postow^{1

3}

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York.
² Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York.
³ Department of Medicine, Weill Cornell Medical College, New York City, New York.

PMID: 39883427
PMCID: PMC11783241 (available on 2026-01-30)
DOI: 10.1001/jamaoncol.2024.6168

No abstract available

Plain language summary

This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1 (anti–PD-1) therapy.